RxDoctor Payments Data

Stephen Hix, NP

Family · Oklahoma City, OKNPI 1477224392

Payments from drug & device makers

$5,284in general payments, 2019–2025

Across 257 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$921
  • AstraZeneca$545
  • Madrigal Pharmaceuticals$396
  • Sanofi$275
  • AbbVie$274
  • Regeneron Healthcare Solutions, Inc.$234
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$5,284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,284 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$70,360
Medicare patients
355
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide135$130,371
Humira PenAdalimumab11$76,775
TrulancePlecanatide25$23,147
CreonLipase/Protease/Amylase12$19,336
MovantikNaloxegol Oxalate29$15,839
Colestipol Hcl129$14,654
Sucralfate152$8,257
SutabSod Sulf/Pot Chloride/Mag Sulf42$6,737
MotegrityPrucalopride Succinate13$5,787
Ursodiol11$4,100
Omeprazole191$3,921
Pantoprazole Sodium197$3,325
Famotidine173$2,772
Dicyclomine Hcl107$2,471
Ondansetron OdtOndansetron85$1,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$274$149,706147 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$187$23,14725 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$921$5,78713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.

Other family in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →